Terms: = Kidney tumors AND RECQL4, RecQ4, 9401, ENSG00000160957, RECQ4, RTS AND Treatment
6 results:
1. treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis.
Rodriguez Faba O; Palou J; Vila Reyes H; Guirado L; Palazzetti A; Gontero P; Vigués F; Garcia-Olaverri J; Fernández Gómez JM; Olsburg J; Terrone C; Figueiredo A; Burgos J; Lledó E; Breda A
Actas Urol Esp; 2017 Dec; 41(10):639-645. PubMed ID: 29126568
[TBL] [Abstract] [Full Text] [Related]
2. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients.
Hinten F; Meeuwis KA; van Rossum MM; de Hullu JA
Crit Rev Oncol Hematol; 2012 Nov; 84(2):161-80. PubMed ID: 22425015
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines.
Huang C; Ramakrishnan R; Trkulja M; Ren X; Gabrilovich DI
Cancer Immunol Immunother; 2012 Apr; 61(4):573-9. PubMed ID: 22223258
[TBL] [Abstract] [Full Text] [Related]
4. The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Koos B; Jeibmann A; Lünenbürger H; Mertsch S; Nupponen NN; Roselli A; Leuschner I; Paulus W; Frühwald MC; Hasselblatt M
Cancer; 2010 Nov; 116(21):5075-81. PubMed ID: 20629032
[TBL] [Abstract] [Full Text] [Related]
5. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Gadd S; Sredni ST; Huang CC; Perlman EJ;
Lab Invest; 2010 May; 90(5):724-38. PubMed ID: 20212451
[TBL] [Abstract] [Full Text] [Related]
6. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.
Donaldson JT; Keane TE; Poulton SH; Walther PJ
Urol Res; 1990; 18(4):245-50. PubMed ID: 2219586
[TBL] [Abstract] [Full Text] [Related]
